Do I have to take medication for ADHD?

Whose guidance applies to you

Worth settling before anything else, because the answer is uneven.

In the US, there is no national adult ADHD guideline. That’s not a gap in this page’s research: APSARD, the American Professional Society of ADHD and Related Disorders, states plainly on its own site that there are currently no guidelines in the United States, which is the reason it’s writing some. On 27 August 2026 it announced that its adult ADHD guidelines had entered a final review stage, with publication anticipated in the autumn.

What that means in practice is that a US reader’s treatment is shaped by their prescriber’s training and judgment, their specialty’s norms, and their insurer’s rules, rather than by a single document anyone can look up. It’s the main reason two clinicians can give you different answers and both be practising reasonably.

In England and Wales there is one, guideline NG87 from NICE, the National Institute for Health and Care Excellence, which sets clinical guidance for the NHS there. It was published in March 2018 and last updated in September 2019. It gets quoted at length on this page for one reason: it’s unusually explicit about the reader’s right to decline, and that explicitness is hard to find elsewhere. Treat it as a well-reasoned reference point rather than as a rule that governs you, unless you happen to be in England or Wales.

The evidence sections further down are a different matter. Randomised trials and meta-analyses don’t have a nationality, and what they found applies wherever you’re reading.

What one health system puts in writing

NICE’s structure for adults puts the situation before the prescription. NICE recommends offering medication to adults with ADHD if symptoms are still causing significant impairment in at least one domain after environmental modifications have been implemented and reviewed. Domains, in the guideline’s own terms, are areas of function such as relationships, education, occupational attainment and risk awareness.

Then it names four separate grounds for going the other way. NICE, the UK’s clinical guidance body, recommends considering non-pharmacological treatment for adults with ADHD who have made an informed choice not to have medication, who have difficulty adhering to it, who have found it ineffective, or who can’t tolerate it. Deciding against medication sits in the same list as medication not working, and neither is treated as the reader being difficult.

When non-pharmacological treatment is what’s indicated, NICE sets a floor rather than leaving it open: as a minimum, a structured supportive psychological intervention focused on ADHD, plus regular follow-up in person or by phone. Treatment may involve elements of, or a full course of, cognitive behavioural therapy.

The guidance also assumes you might want both. NICE recommends considering non-pharmacological treatment in combination with medication for adults who’ve benefited from medication but whose symptoms still cause significant impairment.

What medication does, on the trial evidence

A 2025 adult component network meta-analysis in The Lancet Psychiatry pooled 113 randomised controlled trials covering 14,887 adults.

For core ADHD symptoms at around 12 weeks, stimulants and atomoxetine were the only interventions with beneficial effects supported by both self-reported and clinician-reported ratings. Stimulants showed a standardised mean difference of -0.39 on self-report and -0.61 on clinician report; atomoxetine showed -0.38 and -0.51. Confidence in those estimates ranged between very low and moderate, which is the authors’ own rating and worth carrying alongside the numbers.

One limit from the same paper is straightforward: evidence in the longer term is underinvestigated, since the primary efficacy timepoint was around 12 weeks.

The quality-of-life evidence is less settled than the symptom evidence, and two syntheses from overlapping teams disagree.

Ostinelli and colleagues’ adult-only analysis found medications were not efficacious on additional relevant outcomes such as quality of life. A separate 2025 systematic review and meta-analysis by Bellato and colleagues, drawn from a different dataset, reached the opposite conclusion: across 17 randomised controlled trials and 5,388 participants, amphetamines (Hedges’ g 0.51), methylphenidate (0.38) and atomoxetine (0.30) were all significantly more efficacious than placebo at improving quality of life, with what the authors called a moderate effect size. Its trials covered people aged 6 and over, and the abstract reports the child-versus-adult comparison for atomoxetine only, so this is an all-age estimate whose applicability to adults is directly evidenced for the non-stimulant alone.

Different eligibility rules, populations and methods produced different answers, and Cortese is an author on both, so this isn’t rival camps talking past each other. The defensible conclusion is that quality-of-life effects are less consistent than symptom effects and, where detected, smaller. Not that medication can’t improve life.

On acceptability, within Ostinelli’s analysis, measured as people stopping for any reason, every therapeutic component looked similar to placebo apart from two: atomoxetine at an odds ratio of 1.43 and guanfacine at 3.70, both lower than placebo. Stimulants weren’t among them. Acceptability findings vary between reviews depending on which trials are included and how discontinuation is defined, so that’s a result from one analysis rather than a settled property of the drugs.

So the case for medication is real, specific and short-term. It’s good evidence that core symptoms move, and contested evidence on whether life improves.

What the alternatives look like, and how well they hold up

The same analysis tested non-drug options against placebo, and this is where the picture gets more complicated rather than worse.

Cognitive behavioural therapy, cognitive remediation, mindfulness, psychoeducation and transcranial direct current stimulation all beat placebo on clinician-reported measures, with standardised mean differences from -0.76 to -1.35. Several of those point estimates are larger than the drug ones.

But they beat placebo only on clinician-reported measures. On self-report, the difference didn’t hold. The authors’ summary is that the effects of non-pharmacological strategies were inconsistent across different raters.

That inconsistency is the finding, and the authors report it without resolving it. Within this analysis, no non-drug intervention showed a core-symptom benefit on both self-rated and clinician-rated measures, while stimulants and atomoxetine did.

Anyone telling you that therapy, coaching, exercise or an app matches medication for core ADHD symptoms is going beyond what this shows. Anyone telling you the non-drug options don’t work is also going beyond it. The accurate version is less satisfying: the evidence for them is weaker and less consistent, not absent.

Why people take it, and why people don’t

A 2025 systematic thematic review in the Journal of Affective Disorders synthesised 47 qualitative studies of adults with ADHD published between 1994 and 2023, looking at motivations for medical stimulant use. Qualitative synthesis maps what people say and why; it can’t tell you how common any of it is, and nothing below should be read as a proportion.

Four themes came out of it. People sought treatment in response to tangible effects on academic, occupational and social functioning. They described stimulants improving focus, emotional regulation and daily functioning. They tailored use to particular tasks or times rather than treating it as constant. And the barriers they named were stigma, cost and concerns about dependency, all of which shaped whether they kept taking it.

Stigma turns up in the guidance too. The 2019 updated European consensus statement on adult ADHD, drawn from 63 experts across European and other countries, concluded that the stigma surrounding ADHD, mainly due to lack of knowledge, increases the suffering of patients. It’s a consensus document rather than a systematic review, so treat it as the considered position of a large expert group.

That barrier theme is the one worth sitting with, because two of those three barriers aren’t about the medication at all. Cost is a question about where you live and what you can afford. Stigma is a question about the people around you. Neither tells you whether the medication would help you, and both can be doing a lot of the deciding.

Taking it isn’t all-or-nothing either

The question is usually posed as a switch with two positions, and the qualitative literature suggests people don’t experience it that way.

One of the four themes in that review was the context of use: participants described tailoring medication to specific tasks or specific times rather than treating it as a constant background. That’s a description of what people reported doing, not a recommendation, and how much room you have to do it is a matter for your prescriber and for what you’ve been prescribed.

It matters here because it changes what you’re deciding. “Do I have to take medication?” sounds like a question about becoming a person who takes medication. In practice the people in these studies were making narrower decisions, repeatedly, about particular days and particular demands.

NICE’s own framing points the same way. It asks clinicians to review medication at least annually, covering how well the treatment works throughout the day and the effects of missed doses, planned dose reductions and periods of no treatment. Those are all built into the guidance as things to examine, which means the guidance already assumes a treatment plan is something you adjust rather than something you sign.

Choosing not to, or not yet

If you land on no, NICE has a shape for that rather than a shrug, and it’s worth knowing what to ask for by name even where it isn’t the guidance that governs you.

Under NICE’s adult medication sequence, medication is offered after environmental modifications have been implemented and reviewed. NICE defines them as changes made to the physical environment to minimise the impact of a person’s ADHD on day-to-day life, determined from an assessment of that person’s needs. Its own examples include changes to seating arrangements, changes to lighting and noise, reducing distractions such as with headphones, optimising work or education around shorter periods of focus with movement breaks, and reinforcing verbal requests with written instructions.

The minimum non-pharmacological offer is the structured ADHD-focused psychological intervention and regular follow-up described above, and it’s worth asking for by name if it isn’t offered.

NICE also asks clinicians to encourage adherence to non-drug treatment by discussing the barriers to continuing it, and the list is unusually candid: not being sure whether it’s making a difference, the time and organisational skills needed to commit, the work required between sessions, and the possibility that increased self-awareness is itself hard to carry.

And none of it is a one-way door. NICE asks that people be reassured they can revisit treatment decisions, that they be encouraged to raise any preference to stop or change medication, and that trial periods of stopping or reducing the dose be considered where the balance of benefits and harms suggests it. Deciding against medication this year commits you to nothing about next year, and the same is true in reverse.

What the guidance won’t do is decide for you, and neither will this page. What it does establish is that saying no is a recognised position with a documented pathway attached, not a refusal to be talked out of.